Canada to launch clariti® 1 day multifocal 3 Add Contact Lenses
RICHMOND HILL, ON., November 4, 2024—Reflecting its steadfast commitment to continuous innovation, CooperVision announced the immediate Canadian availability of its new clariti® 1 day multifocal 3 Add contact lenses. Several of the company’s advanced technologies are combined in the new lens to provide all-day comfort, ease of fit and the widest range, to meet the needs of more patients.*2,3
clariti® 1 day multifocal 3 Add features the CooperVision Binocular Progressive System®, an innovative 3 Add design that caters to all levels of presbyopia to provide optimal visual acuity at all distances.4 The design offers the additional advantage of a simplified fitting process to make it easier for practitioners to fit patients with the right lens, without the need for extended chair time.3
With a focus on maximizing patient comfort, CooperVision utilized its proprietary Optimized Comfort Edge™—an upgraded edge design—in the clariti® 1 day multifocal 3 Add contact lens to provide a high level of comfort from the first fit.5,6 The new lens pairs this design with WetLoc® Technology, which creates a naturally wettable lens that locks in moisture to help keep lenses moist throughout the day, supporting all-day comfort.*
“As our R&D teams continuously advance contact lens technology, we actively look for ways to extend meaningful innovations across other products, so that more practices and wearers can benefit,” said Michele Andrews, OD, Vice President, Marketing and Professional & Academic Affairs, Americas, CooperVision. “The addition of the Binocular Progressive System®—the same multifocal design first introduced in the highly regarded MyDay® multifocal—elevates the performance of clariti® 1 day multifocal 3 Add, including the incredible fit success.”
In a clinical study, a remarkable 98% of patients were fit with their final clariti® 1 day multifocal 3 Add prescription with two pairs of lenses or fewer.3,7,8
To further enable prescribing for more patients, the new clariti® 1 day multifocal 3 Add is available in the industry-leading range of +8.00D and -12.00D, providing more sphere powers than any other competitive 1-day multifocal lens.2
“A lot of patients who have grown up not requiring any vision correction get to a point in their 40s where they suddenly experience changes in their vision. This is all new to them and can bring on frustration.” said Dr. Michael Shaheen, OD, Hills & Dales Vision, Inc. “Offering solutions like the clariti® 1 day multifocal 3 Add lens gives patients the ability to see without help from glasses, giving them their freedom back.”
It is estimated that 128 million Americans currently have presbyopia, and recent data reveals that 40% of new contact lens wearers are over the age of 40, pointing to substantial opportunity for practices to fit more multifocal contact lenses.9,10
For more information, visit clariti® 1 day multifocal 3 Add | CooperVision Practitioner.
###
*Manufacturer's quoted core water content.
References:
1. CVI data on file, 2022.
2. CVI data on file 2024. Based on prescription option combinations (sph and add) available across all daily disposable multifocal soft lenses from CVI, JJV, B+L and Alcon in USA Feb 2024.
3. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; n=90.
4. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; with ratings from 85 to 89 out of 100; n=90 habitual MFCL wearers.
5. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add with a rating of 88 out of 100; n=90 habitual MFCL wearers.
6. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; with a rating of 93 out of 100; n=90 habitual MFCL wearers.
7. CVI data on file 2020. Prospective, double-masked, bilateral, one-week dispensing study UK with MyDay® multifocal; n=104 habitual multifocal contact lens wearers.
8. CVI data on file 2021. Prospective, subject-masked, randomized, bilateral, two-week dispensing study at 5 US sites with MyDay® multifocal; n=58 habitual multifocal contact lens wearers.
9. Timothy R. Fricke, MSc. Nina Tahhan, PhD. Serge Resnikoff, MD. Eric Papas. Anthea Burnett. Suit May Ho. Thomas Naduvilath. Kovin S. Naidoo. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia. American Academy of Ophthalmology. Published May 9, 2018.
10. GfK 2024 – All rights reserved, 1/2024.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week, and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, visit www.coopercos.com
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding a product launch and features and technologies that may impact demand for new products. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to research and development, regulatory requirements, clinical studies, sales, marketing, and distribution plans and capabilities; potential product performance and quality issues; intellectual property risks; competition; and other factors described in CooperCompanies’ Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper’s Annual Report on Form 10-K for the fiscal year ended October 31, 2023, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company’s analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
Media Contact
Heather Kowalczyk, APR
McDougall Communications for CooperVision
heather@mcdougallpr.com or 585-434-2148
SA*12527